AMETEK, Inc. Q4 FY2025 earnings call

Management Statement and Operational Highlights

• Strong Q4 Performance: AMETEK had record sales, orders, operating income, EBITDA, diluted earnings per share, operating cash flow, and free cash flow in Q4 2025. Ended the quarter with a record backlog and announced the acquisition of LKC Technologies.
• Acquisitions: In 2025, completed acquisitions of Ferro Technologies and Kern Micro Technique, with integration going well. LKC Technologies acquisition broadens med tech exposure.
• Capital Deployment: Robust balance sheet, strong cash flows, focus on acquisitions, share repurchases, dividends, and $100 million R&D investment in 2026. Vitality index at 30% in Q4 2025.
• Operational Examples: Spectro's new product family, defense businesses' growth, Rotron and Ear Technology's cooling solutions, Abaco's high-performance computing systems, and power/data systems for UAVs.

Segment Performance

• Electronic Instruments Group (EIG): Q4 sales were $1.37 billion, up 13% from Q4 2024. Organic sales grew 2%, acquisitions added 10 points, and currency was a 1% tailwind. Operating income was a record $413.7 million, up 7%, with core operating margins at 32.3%, up 50 basis points.
• Electromechanical Group (EMG): Q4 sales were $629 million, up 15% from Q4 2024. Organic sales grew 14%, and currency was a 1% tailwind. Operating income was $142.5 million, up 28%, with operating margins at 22.7%, up 240 basis points.
• Full Year 2025: Overall sales were $7.4 billion, up 7% from 2024. Operating income was $1.94 billion, up 7%, with operating margins at 26.2%, up 10 basis points. Core margins were up 80 basis points. EBITDA was $2.33 billion, up 7%, with EBITDA margins at 31.5%. Diluted earnings per share were $7.43, up 9% from 2024.

Guidance

• 2026 Sales: Overall sales expected to be up mid-single digits, organic sales up low to mid-single digits.
• Diluted EPS: Expected to be in the range of $7.87 to $8.07, up 6% to 9% compared to 2025.
• Q1 2026: Overall sales expected to be up approximately 10% versus Q1 2025; adjusted earnings $1.90 to $1.95 per share, up 6% to 9% versus Q1 2025.
• Financials: G&A expenses, other expenses, tax rate, capital expenditures, depreciation, operating working capital, free cash flow, and debt details provided with 2026 expectations.

Risks

• Macroeconomic uncertainties, including inflation, tariffs, and deglobalization, which could impact sales and margins.

Question and Answer

Q: Drill deeper into medical portfolio performance and strategic price capture.

A: Dave Zapico states there was a positive price cost spread in 2025 offsetting inflation and tariffs, expecting similar in 2026 with differentiated products in niche markets.

Q: Backlog conversion in 2026.

A: Dave Zapico says backlog conversion is in the same ballpark, with strong orders throughout the quarter and December being the strongest record month.

Q: FARO acquisition progress.

A: Dave Zapico talks about FARO's strategic fit with CreateForm, synergy plans to double EBITDA margins, and integration progress.

Q: China market performance.

A: Dave Zapico mentions strong performance in China, with products suited to local manufacturing, automation, and clean environment needs.

Q: M&A pipeline in 2026.

A: Dave Zapico says there's a strong M&A pipeline with high-quality deals, disciplined approach, and ability to deploy over $5 billion while maintaining investment-grade credit rating.

Q: Margin trajectory in 2026.

A: Dalip Puri and Dave Zapico discuss core margins, incremental margins, and progress on FARO and Paragon synergies to improve margins.

Q: Orders trends and market segments.

A: Dave Zapico talks about broad-based orders growth, with EMG and EIG contributing, and continued strength in aerospace and defense businesses.

Q: Medical portfolio and new deal.

A: Dave Zapico discusses LKC Technologies' advanced eye care testing instruments, its technology fit with AMETEK, and recurring revenue aspect.

Q: EMG margin potential.

A: Dave Zapico states EMG is on track to achieve mid-twenty percent operating margins in 2026 and grow further.

Q: Vitality index and defense business.

A: Dave Zapico talks about the vitality index, defense business' strong performance, and opportunities in European defense spending.

Q: Process business growth and R&D.

A: Dave Zapico mentions process business improvement, R&D investments, and potential growth in research areas despite previous challenges